E. Robin

发表

Biologic characteristics of patients with hypocellular myelodysplastic syndromes.

P. Venugopal, S. Mundle, K. Allampallam, 1999, Leukemia research.

High‐dose, multiple‐alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non‐small cell lung cancer

H. Golomb, J. Bitran, P. Hoffman, 1989, Cancer.

Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes.

P. Venugopal, D. Rosi, A. Raza, 1996, Blood.

Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship.

A. Raza, R. Borok, S. Gregory, 1997, Leukemia & lymphoma.

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

P. Venugopal, M. Showel, M. Klein, 1996, Leukemia research.

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

P. Venugopal, A. Raza, R. Borok, 1996, International journal of hematology.

OPEN FORUM A paradigm shift in myelodysplastic syndromes

P. Venugopal, H. Preisler, Stan Rifkin, 2019 .

Pilot Study of Pentoxifylline and Ciprofloxacin with or without Dexamenthasone Produces Encouraging Results in Myelodysplastic Syndromes

P. Venugopal, H. Preisler, A. Raza, 1998 .

A paradigm shift in myelodysplastic syndromes.

P. Venugopal, H. Preisler, A. Raza, 1996, Leukemia.

Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine.

P. Venugopal, M. Showel, A. Raza, 1997, Experimental hematology.

A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.

S. Purl, C. Westbrook, J. Bitran, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows.

P. Venugopal, S. Gregory, S. Mundle, 1999, International journal of hematology.

Prognostic factors in patients with non‐small cell bronchogenic carcinoma and brain metastases

T. Demeester, H. Golomb, S. Newman, 1982, Cancer.

Phase II study of mitoxantrone and ketoconazole for hormone‐refractory prostate cancer

R. Bergan, M. Pins, B. Jovanovic, 2006, Cancer.

Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe

N. Hanna, Ziyue Liu, Y. Tong, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.

M. Galsky, M. Milowsky, Menggang Yu, 2019, Journal of Clinical Oncology.

Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4.

P. Venugopal, H. Preisler, R. Huang, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.

P. Venugopal, A. Raza, R. Huang, 2000, Blood.

Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).

T. Bekaii-Saab, B. El-Rayes, B. O'Neil, 2019, European journal of cancer.

Multimodality therapy of stage III adenocarcinoma of the breast

W. Recant, J. Bitran, H. Rochman, 1983, Journal of surgical oncology.

Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients

P. Venugopal, A. Raza, S. Gregory, 2000, Hematology.